

Press Release

Matthias Link
Corporate Communications

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2872
F +49 6172 608-2294
matthias.link@fresenius.com
www.fresenius.com

May 20, 2015

Fresenius SE & Co. KGaA Annual General Meeting: 2015 guidance confirmed, 22nd consecutive dividend increase approved

Fresenius expects to set new sales and earnings records in 2015. Ulf Mark Schneider, CEO of Fresenius, confirmed the company's growth targets at the Annual General Meeting in Frankfurt today. The global healthcare group forecasts sales growth of 7 to 10 percent and an increase in net income of 13 to 16 percent this year, both in constant currency. After a strong first quarter, Fresenius had raised its earnings guidance in April.

"We are very confident that our steady, strong growth will continue," Schneider said. "The demand for healthcare continues to rise around the world. In industrialized countries, it is driven primarily by increasing life expectancies and health awareness. Globally, more people are gaining access to high-quality healthcare. Many of the biggest emerging market countries are rolling out comprehensive, nationwide healthcare coverage."

Shareholders voted with a majority of 88.67% to approve the 22nd consecutive dividend increase proposed by the general partner and the Supervisory Board. The dividend was raised by 6% to €0.44 per share.

The Annual General Meeting, with a majority of 98.23%, elected Michael Diekmann as a new member of the Supervisory Board of Fresenius SE & Co. KGaA. Diekmann, who was CEO of Allianz SE from 2003 until this year, will seek election as Deputy

Chairman. The new election was necessary following the death of Dr. Gerhard Rupprecht, Supervisory Board's Deputy Chairman, in 2014.

Shareholder majorities of 99.61 and 97.99%, respectively, approved the actions of the Management and Supervisory Boards in 2014.

At the Annual General Meeting, 73.97% of the subscribed capital was represented.

Note to the media: Images of the Annual General Meeting can be found at www.fresenius.com/5689_5893.htm.

#

Fresenius is a global health care group, providing products and services for dialysis, hospital and outpatient medical care. In 2014, Group sales were €23.2 billion. On March 31, 2015, the Fresenius Group had 217,836 employees worldwide.

For more information visit the Company's website at www.fresenius.com.

Follow us on Facebook and Twitter: www.facebook.com/fresenius_group and www.twitter.com/fresenius.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Dr. Ulf M. Schneider (Chairman), Dr. Francesco De Meo, Dr. Jürgen Götz, Mats Henriksson, Rice Powell, Stephan Sturm, Dr. Ernst Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick